Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Pfizer reported positive topline results from the TRANQUILLO Phase 3 program for LITFULO in nonsegmental vitiligo, with both pivotal studies meeting their co-primary endpoints for facial and total body repigmentation. The trials, which enrolled 2,174 patients across 271 sites, demonstrated significant improvement versus placebo at Week 52 with a safety profile consistent with the drug's established use in alopecia areata.
Key figures
- Drug Name
- LITFULO (ritlecitinib)
- Phase Of Trial
- Phase 3
- Sites
- 271
- Week 52
- Yes
- Doses mg
- [50,100]
- Patient count
- 2174
- Primary endpoints met
- ["F-VASI75","T-VASI50"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.